

August 1, 1968

Dr. Francis J. Braceland, Editor  
American Journal of Psychiatry  
1700 Eighteenth St., N.W.  
Washington, D.C. 20009

Dear Dr. Braceland:

Enclosed are draft copies of two reports summarizing our experiences with a narcotic antagonist, cyclazocine. Following theoretical models which have been of interest for many years, we found that cyclazocine had a neurophysiological profile similar to imipramine. These clinical trials, in two different populations, indicate that cyclazocine does indeed have significant clinical antidepressant activity.

We are aware that such open clinical studies are ordinarily of limited value since enthusiasm may effect the treatment outcome in depressive populations. But the demonstration of a significant application of available neurophysiologic methods provides our incentive to present this publically.

We would appreciate your consideration for publication, and ask that the two reports be assessed together.

Thank you for your consideration.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kp

enc. (2)